Interview with Dominique Demolle , Co-founder & CEO, Aepodia
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Address: Avenue Albert Einstein 2A
1348 Louvain-la-Neuve
Belgium
Tel: +32 (0)10 39 20 11
Web: http://http/www.aepodia.com
Aepodia S.A. (spin-off of a top 10 US Pharma Company) was created in March 2007 by a group of experts in early-phase clinical development. Since then, our company has grown and built a strong and a worldwide reputation in the early clinical drug development sector. We have established solid and effective collaborations with world pharmaceutical leaders, as well as with small biotech companies. The management and staff members have a background in pharmaceutical development that allows us to understand sponsor requirements and challenges and to meet their needs in an optimal way.
Our headquarters are located in Louvain-La-Neuve, Belgium, with offices in Paris-La Défense, France. Thanks to our strategic location in the center of Europe, we can cover the European phase I units. We also support clinical trials in the United-States and Singapore and provide easy access to patients.
Aepodia is a CRO sponsor representative providing customized services in Phase I/II clinical trials and in clinical development of Medical devices.
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period…
Let us begin by getting an overview of APB’s functions & objectives and your role within the association as General Manager? The Belgian Association of Pharmacists is a federation of…
Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to…
Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager…
Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated…
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is…
Mr. De Cuyper, can you start with a brief introduction to the federal agency for medicines and health products (famhp) and its role within the Belgium’s complex regulatory environment? We…
Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing…
In your 8 years of experience within the group, how would you classify the competitive advantages derived for the company’s unique familial ownership structure? Due to its history and strong…
See our Cookie Privacy Policy Here